Brain-reactive antibodies and disease.

Area of Science:

• Neuroimmunology
• Neurology
• Pathology

Background:

• Autoimmune diseases affect 5-7% of the global population, frequently involving autoantibodies.
• Brain-reactive antibodies are found in 2-3% of the general population but usually don't cause brain pathology.
• Antibodies typically access brain tissue only during early development or in pathological states.

Purpose of the Study:

• To clarify the role of autoantibodies in central nervous system (CNS) diseases.
• To highlight the potential pathogenicity of brain-reactive antibodies.

Main Methods:

• Review of existing literature on autoantibodies and CNS pathology.
• Analysis of factors influencing antibody penetration and pathogenicity in the brain.

Main Results:

• The restricted access of antibodies to the brain and inconsistent serum titer correlations have historically delayed understanding their CNS impact.
• Evidence suggests antibodies can indeed damage the brain, potentially initiating or exacerbating neurological conditions.
• Brain-reactive antibodies are implicated in the symptomatology of autoimmune, infectious, and malignant diseases affecting the CNS.

Conclusions:

• Autoantibodies play a significant, though often underestimated, role in neurological diseases.
• Understanding antibody-mediated CNS damage is crucial for diagnosing and treating various neurological disorders.
• Further research is warranted to fully elucidate the mechanisms and clinical relevance of autoantibodies in the central nervous system.